The FDA Panel That Could Change TRT Forever: What It Means for You

On December 10, 2025, something remarkable happened. The FDA convened a 13-member expert panel — primarily urologists and federal health officials — to examine how testosterone replacement therapy is regulated in the United States. Their conclusion was unanimous and sweeping: the current rules are outdated, not supported by modern evidence, and are actively harming patients.

This wasn't a minor policy tweak. The panel recommended changes that could fundamentally reshape how millions of men access testosterone therapy. If adopted, these recommendations would remove barriers that have existed since 1990 and finally align FDA policy with what the medical evidence has been saying for years.

Here's what happened, what it means, and what you should expect going forward.

What Happened at the FDA Panel

FDA Commissioner Marty Makary opened the December 10 meeting by drawing a parallel to the agency's recent decision to remove black box warnings from hormone replacement therapy for women. He noted that outdated safety concerns had prevented women from accessing beneficial treatments for years — and suggested the same thing might be happening with testosterone therapy for men.

"According to the Journal of Clinical Endocrinology and Metabolism, 5.6% of men aged 30 to 79 have low testosterone and symptoms," Makary said during the hearing. "Why are we ignoring this topic?"

The panel then heard presentations from some of the most prominent researchers in men's health, including Dr. Mohit Khera from Baylor College of Medicine (a lead investigator on the landmark TRAVERSE trial), Dr. Helen Bernie from Indiana University, and Dr. Landon Trost, founder of the Male Fertility and Peyronie's Clinic.

The consensus was clear: the science has moved far beyond the regulations.

The Four Major Recommendations

1. Remove Testosterone's Schedule III Controlled Substance Status

This is the big one. Since 1990, testosterone has been classified as a Schedule III controlled substance — the same category as ketamine and codeine. This happened because of the Anabolic Steroids Control Act, which was a political response to doping scandals in the 1980s, not a decision based on clinical science.

As Dr. Khera pointed out during the hearing: "We give patients human chorionic gonadotropin, which raises testosterone. We give patients clomiphene, which raises testosterone. None of these are considered controlled substances, but they do the exact same thing."

Estrogen — the equivalent hormone for women — has never been a controlled substance. The panel called this inconsistency indefensible.

What this classification means in practice: doctors must maintain special DEA registrations to prescribe testosterone, pharmacies may limit how much they stock, and every prescription is tracked through state prescription drug monitoring programs. All of this creates friction that discourages primary care doctors from prescribing TRT — which, ironically, has pushed patients toward less-regulated "T clinics" and telehealth platforms.

2. Expand FDA Indications to Include Age-Related Low Testosterone

Currently, the FDA only approves TRT for men who have low testosterone caused by a specific medical condition — things like pituitary tumors, genetic disorders, or testicular injury. This is called "classical hypogonadism," and it represents a small fraction of men who actually benefit from treatment.

The reality? Approximately 85% of current testosterone prescriptions are technically off-label, prescribed for men whose low T stems from aging, obesity, metabolic disease, or other factors not on the FDA's approved list. The American Urological Association and the Endocrine Society both recommend TRT for men with confirmed low testosterone levels and clinical symptoms — regardless of the underlying cause.

The panel recommended aligning the FDA label with these clinical guidelines, which would legitimize the treatment millions of men already receive.

3. Remove the Prostate Cancer Warning

For decades, testosterone product labels have carried warnings suggesting TRT may increase prostate cancer risk. This belief dates back to a 1941 study and was never supported by modern randomized controlled trial data.

The TRAVERSE trial — the largest randomized controlled trial of TRT ever conducted — definitively showed no increased risk of prostate cancer in men receiving testosterone therapy. The panel recommended removing this outdated warning from all testosterone product labels.

4. Implement Routine Testosterone Screening for Men Over 40

Just as doctors routinely check cholesterol levels and blood pressure, the panel suggested that testosterone should become part of standard health screening for men over 40. This would help catch testosterone deficiency early, before it contributes to metabolic syndrome, cardiovascular disease, or reduced quality of life.

Why Is This Happening Now?

Three converging factors brought us to this moment:

The TRAVERSE trial changed everything. Published in the New England Journal of Medicine in 2023, this trial of 5,246 men definitively showed that TRT does not increase cardiovascular risk or prostate cancer risk. This dismantled the two biggest safety objections that had kept regulations tight for decades. In February 2025, the FDA had already removed the cardiovascular black box warning from all testosterone products based on this data.

The generational testosterone decline is accelerating. Research using NHANES data shows that testosterone levels in American men have been declining steadily — even after controlling for age and BMI. A 30-year-old man today often has testosterone levels comparable to a 60-year-old from previous generations. This isn't just about aging; it's a population-level shift driven by obesity, environmental factors, and lifestyle changes.

Testosterone prescriptions have already surged. U.S. prescriptions went from 7.3 million in 2019 to over 11 million by 2024. The fastest-growing demographic is men aged 25-44, with usage increasing by 86% in the 25-34 age group between 2018 and 2022. The market has already moved — regulations are catching up.

The TRAVERSE Trial: The Study Behind Everything

The TRAVERSE trial deserves special attention because it's the foundation for nearly every regulatory change we're seeing.

Designed at the FDA's request after earlier safety concerns, TRAVERSE enrolled 5,246 men aged 45-80 who had documented hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. This was intentionally a high-risk population — the idea was to stress-test testosterone's safety in the men most likely to have problems.

The results, published in 2023 after a mean follow-up of 22-33 months:

The primary finding — non-inferiority for major cardiovascular events — was the data point that changed the regulatory landscape. TRT didn't cause more heart attacks, strokes, or cardiovascular deaths than placebo, even in men who already had heart problems.

The trial did find a small increase in blood pressure, atrial fibrillation, and acute kidney injury — which is why the FDA added blood pressure monitoring to the updated label rather than removing all warnings. This is a balanced, evidence-based approach: acknowledge the real risks, remove the unfounded ones.

What Could Actually Change for Patients

If the panel's recommendations are adopted, here's what could change for men seeking or currently on TRT:

Easier access through primary care. Removing the controlled substance designation would make many primary care doctors more comfortable prescribing testosterone. Currently, the DEA tracking and special registration requirements discourage GPs from offering TRT, even when it's clinically appropriate.

Lower costs. Controlled substances require special handling, tracking, and security measures throughout the supply chain. Removing this designation could reduce costs at the pharmacy level. Insurance coverage could also improve if the FDA expands approved indications to include age-related low T.

Telehealth access stabilized. The DEA's temporary telemedicine flexibilities for controlled substances are currently extended through December 31, 2026. If testosterone is descheduled, the question of telehealth prescribing becomes much simpler — no more worrying about whether temporary rules will be extended or expire.

Less stigma. The controlled substance label carries cultural weight. Many men hesitate to seek treatment because they associate testosterone with "steroids" or "performance-enhancing drugs." Removing this classification helps normalize testosterone therapy as the legitimate medical treatment it is.

Realistic Timeline for Changes

It's important to be realistic: FDA panels make recommendations, but the FDA isn't required to adopt them. Here's a likely timeline:

Already done (February 2025): The FDA removed the cardiovascular black box warning from all testosterone products.

In progress (2026): The FDA's public comment period on expanded testosterone access is underway. Commissioner Makary has signaled openness to changes, but the formal rulemaking process takes time.

Prostate cancer warning removal (likely 2026-2027): This is the most straightforward change, given the TRAVERSE data. Expect updated labeling within the next 12-18 months.

Expanded indications (uncertain): Broadening the approved use of TRT to include age-related hypogonadism is a more complex regulatory action. It could take 2-3 years to work through the formal process.

Descheduling (longest timeline): Removing testosterone from the controlled substances list requires DEA action, not just FDA action. This involves a separate regulatory process and could face political resistance. Timeline: 2-5 years, if it happens at all.

What You Can Do Right Now

While regulatory changes work through the system, the practical reality for patients hasn't changed overnight. Here's what matters today:

If you're considering TRT: The science supporting testosterone therapy for men with confirmed low T and symptoms is stronger than ever. Don't let outdated stigma prevent you from having a conversation with your doctor or exploring online clinics. The TRAVERSE trial data gives both you and your provider confidence that, when properly monitored, TRT is a safe and effective treatment.

If you're currently on TRT: Continue your protocol and monitoring schedule. The regulatory changes don't affect how TRT works — they affect how it's regulated. Your treatment plan remains the same.

If your doctor has been hesitant: The FDA panel's recommendations and the TRAVERSE trial data are powerful tools in a conversation with a reluctant provider. If your primary care doctor still won't consider TRT, specialized online clinics offer an alternative path to care.

The December 2025 FDA panel marked a turning point for testosterone therapy in the United States. For the first time, the people responsible for regulating TRT are acknowledging what researchers and patients have known for years: the current rules don't match the science, and millions of men are paying the price for outdated policy.

Change won't happen overnight, but the direction is clear. Testosterone therapy is moving from the fringes toward the mainstream of men's healthcare — and the evidence is on its side.